| Trial Identifier: | D5161C00017 |
| Sponsor: | AstraZeneca |
| NCTID:: | NCT05215951 |
| Start Date: | July 2022 |
| Primary Completion Date: | March 2023 |
| Study Completion Date: | March 2023 |
| Condition: | Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| Chinese (Simplified) Translation |
| Country | Location |
|---|---|
| CN | Changsha, CN, 430033 |
| CN | Chengdu, CN, 610072 |
| CN | Chengdu, CN, 610042 |
| CN | Chengdu, CN, 610041 |
| CN | Harbin, CN, 150049 |
| CN | Mianyang, CN, 621000 |
| CN | Nan Chong, CN, 637000 |
| CN | Wenzhou, CN |
| CN | Yibin, CN, 644000 |
| CN | Zhengzhou, CN, 450000 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company